Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis

Leibo Wang; Guanyu Shi; Guoqiang Zhao; Wei He; Zhuangding Cen; Feng Xu

doi:10.1097/CAD.0000000000001449

Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis

Anticancer Drugs. 2023 Apr 1;34(4):473-478. doi: 10.1097/CAD.0000000000001449. Epub 2022 Nov 18.

Authors

Leibo Wang¹, Guanyu Shi², Guoqiang Zhao¹, Wei He¹, Zhuangding Cen¹, Feng Xu¹

Affiliations

¹ Department of Surgery, Guizhou Orthopaedic Hospital, Guiyang.
² Department of Urology, Fenggang County People's Hospital, Zunyi, China.

PMID: 36730481
DOI: 10.1097/CAD.0000000000001449

Abstract

This study aimed to investigate whether Enfortumab vedotin (EV) is suitable for patients with locally advanced or metastatic urothelial carcinoma and to perform a meta-analysis of its efficacy and safety. Five studies involved 584 patients were included in the meta-analysis. The results of single-arm meta-analysis showed that with EV at 1.25 mg/kg, the objective response rate (ORR) was 47%. The meta-analysis indicated that EV showed good efficacy and safety in the patient population of locally advanced or metastatic urothelial carcinoma.

Publication types

Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / adverse effects
Carcinoma, Transitional Cell* / drug therapy
Humans
Urinary Bladder Neoplasms* / pathology
Urologic Neoplasms* / drug therapy
Urologic Neoplasms* / pathology

Substances

enfortumab vedotin
Antibodies, Monoclonal